



Research Article

Routine Probiotics Decrease the Incidence of Necrotizing Enterocolitis in Extremely Low Birth Weight Infants < 1000 Grams

Stefanie Rutz¹ and Luke Jardine^{1,2*}¹Mater Mothers' Hospital, Australia²School of Medicine, The University of Queensland, Australia

Abstract

Objectives: To determine the effects of routine probiotics on necrotizing enterocolitis (NEC) rates in a large tertiary Australian neonatal unit.

Methods: Retrospective cohort study of infants born < 32 weeks of gestation between 1st of November 2011 and 31st of October 2013. Data were collected over two periods, before and after introduction of probiotics (*Lactobacillus acidophilus* and *Bifidobacterium bifidum*). A subgroup analysis was carried out for extremely low birth weight (ELBW) infants. Confirmed NEC was defined as stage II or more as per modified Bell's criteria. T-tests or Wilcoxon Tests were used to compare continuous variables and Chi-square or Fisher's exact test to compare categorical variables. Logistic regression was used to assess perinatal variables that might influence the risk of NEC.

Results: 297 untreated infants were compared with 283 infants who received probiotic prophylaxis. The incidence of NEC was significantly lower with probiotic treatment (4.4 versus 1.1%, p-value 0.02). The effect was more pronounced in ELBW infants, 11 of 89 untreated infants developed confirmed NEC versus 2 of 98 exposed infants (12.4% versus 2%, p-value 0.008). There were no episodes of sepsis with the administered probiotic species.

Conclusions: Prophylactic therapy with *L. acidophilus* and *B. bifidum* resulted in a statistically significant benefit. In ELBW infants, the number needed to treat to prevent one case of NEC was 10.

Keywords

Necrotizing enterocolitis, Probiotics, Preterm infants, Extremely low birth weight infant

Introduction

Necrotizing enterocolitis (NEC) is the most common serious acquired disease of the gastrointestinal tract in preterm infants [1]. Although it can occur in full-term neonates, almost 90% of all cases occur in premature infants [2]. Both incidence and case fatality rates increase with decreasing birth weight and gestational age [2]. The majority of cases occur in very low birth weight infants with an incidence of approximately 6 to 7% [3-5]. In ELBW infants reported NEC rates range between 10 and 11% [4-6].

The pathology of NEC is primarily due to changes from ischemic necrosis and inflammation [7,8]. The pathogenesis of NEC remains incompletely understood, but it is probably a heterogeneous disease resulting from multiple factors that result in mucosal injury in a susceptible host [8-10]. Factors implicated in the pathogenesis of NEC include prematurity, enteral feeding, microbial bowel overgrowth, impaired mucosal defence, excessive inflammation, circulatory instability of the intestinal tract and medications that cause intestinal mucosal injury or enhance microbial overgrowth [2,7,11-22]. There is strong evidence that human milk

reduces the risk of NEC in premature infants [23-25]. Several risk factors have been shown to be associated with NEC, such as absent or reversed end diastolic flow, persistent ductus arteriosus (PDA), anaemia of prematurity and red blood cell transfusions, however a causal relationship has not been established [26-28]. Antenatal corticosteroids are associated with a reduction in NEC [29,30].

The diagnosis of NEC is based upon the presence of the characteristic clinical features of abdominal distension and rectal bleeding, and the abdominal radiographic finding of pneumatosis intestinalis [2]. Results of laboratory evaluation, including blood studies and stool analysis, are nonspecific

***Corresponding author:** Luke Jardine, Associate Professor, Mater Mothers' Hospital; School of Medicine, The University of Queensland, Brisbane, Queensland, Australia

Accepted: March 19, 2019

Published online: March 21, 2019

Citation: Rutz S, Jardine L (2019) Routine Probiotics Decrease the Incidence of Necrotizing Enterocolitis in Extremely Low Birth Weight Infants < 1000 Grams. Arch Pediatr Surg 3(1):45-52



but may be supportive of the diagnosis of NEC [31,32]. The modified Bell staging criteria defines the different stages of NEC based upon the severity of clinical findings [33,34].

With an early diagnosis, NEC can be treated medically through cessation of feeds, use of parenteral nutrition and antibiotic treatment [2]. Although early recognition and aggressive treatment of this disorder has improved clinical outcomes, NEC accounts for a high mortality and substantial long-term morbidity in survivors of neonatal intensive care. Reported mortality rates range from 10 to 30% and also are inversely related to birth weight [35,36]. 25 to 50% of survivors require surgical intervention [37]. Bowel perforation occurs in one third of the affected infants [1]. Stricture formation, primarily in the colon, occurs in approximately 15% of affected infants [36]. NEC is the most common cause for short bowel syndrome [38].

Probiotic bacteria are live microbial supplements that colonize the gastrointestinal tract and potentially provide benefit to the host [39]. The use of probiotic therapy has been proposed to reduce bacterial overgrowth of more invasive bacteria and promote commensal intestinal bacteria, which inhibit inflammatory pathways, thereby decreasing the risk of NEC [16]. Potential mechanisms by which probiotics may protect high risk infants from developing NEC include increased barrier to migration of bacteria across the mucosa, competitive exclusion of potential pathogens, modification of host response to microbial products, augmentation of IGA mucosal responses, enhancement of enteral nutrition that inhibits the growth of pathogens, and up-regulation of immune responses [40-44]. The most frequently used probiotics are lactobacillus and bifidobacterium [45].

To date, several meta-analyses concluded that supplementation of probiotics reduces the incidence of severe NEC and all cause mortality [45-51]. While these meta-analyses didn't reveal any significant side effects and in fact showed that the use of probiotics didn't increase the risk of sepsis [45,46,48-50], there are case reports of Bifidobacterium bacteraemia in preterm infants on probiotic therapy [52,53]. Debate still remains about the safety of probiotics, their long term effect, the most effective preparations, as well as timing and length of therapy [54-56]. There is insufficient data with regard to the benefits of probiotic supplementation in the most at risk infants weighing less than 1000 grams at birth [57,58].

Methods

Routine probiotic supplementation was introduced on the first of November 2012 for all neonates < 32 weeks of gestation. We conducted a retrospective audit of all neonates < 32 weeks of gestation born between 1 November 2011 and 31 October 2013. Patient data were obtained from medical records and the neonatal and maternal databases of the hospital. Data were divided into two periods, period 1 (before probiotics; 1 November 2011 - 31 October 2012) and period 2 (after routine introduction of probiotics; 1 November 2012 - 31 October 2013). Infants with major congenital anomalies were excluded.

Probiotics supplementation consisted of Lactobacillus acidophilus (NCDO 1748; National Collection of Dairy Organisms) 10⁹ colony-forming units plus Bifidobacterium bifidum (NCDO 1453; National Collection of Dairy Organisms, Reading, United Kingdom) 10⁹ colony-forming units (Infloran™, Laboratorio Farmaceutico, Italy). Probiotics solution was prepared by the nursing staff using a standard method, 1 capsule of Infloran 250 mg was dissolved in 2 mL of mothers' unwarmed expressed milk, donor expressed breast milk or infant formula at the bedside immediately before dose is due. The dose for preterm infants on minimal enteral feeds was one mL of prepared probiotics supplementation, this was increased to 2 mL once feeds had reached a minimum of 3 mL every 2 hours and continued once daily with feedings until 36 weeks' postmenstrual age.

Primary outcomes were incidence of NEC and death, secondary outcomes were time to establish full feeds, time to regain birth weight, duration of parenteral nutrition, duration of central lines and duration of hospitalization. Confirmed NEC was defined as stage II or more as per modified Bell's criteria [34].

This study was approved by the hospital research ethics committee.

Statistical Analysis

Data was assessed for normality. For continuous variables, unpaired t-test or two-sample Wilcoxon Test was applied. For categorical variables, Chi-square test of independence or Fisher's exact test was used. P-values < 0.05 were considered statistically significant. Logistic regression was used to assess perinatal variables that might influence the risk of NEC. Statistical analysis was performed using the R and R commander (<http://cran.r-project.org/>). If sufficient numbers were identified, we planned to do a subgroup analysis for the ELBW infants.

Results

We identified 607 premature infants born at less than 32 weeks of gestation by using existing hospital databases. 9 out of 306 infants in the control group and 15 out of 301 infants were excluded due to major congenital anomalies.

Two further infants in the treatment group had to be excluded because their charts could not be located. Neither of those two infants had confirmed NEC as per our neonatal data base however one of them died soon after birth due to severe depression at birth and hypoxic ischaemic encephalopathy. One infant in the treatment group developed confirmed NEC on day 17 of life prior to the introduction of probiotics. This baby received their first dose of probiotics at 46 days of age on the first of November 2012. This infant has been excluded from the study. Data was therefore analysed for 297 infants in the control group and 283 infants in the treatment group (Figure 1). A subgroup analysis was performed for ELBW infants, 89 infants in the control group and 98 infants in the treatment group.

Both groups had similar patient characteristics (Table 1). There were no significant differences in gestational age, birth




Figure 1: Subject enrolment flow chart.

Table 1: Demographic data and clinical variables.

	Period 1	Period 2	P-value
	Control group	Treatment group	
	No probiotics	Infloran	
	(N = 297)	(N = 283)	
Patient characteristics			
- Median GA † (in days) (IQR 25-75%)	189 (167-208)	189 (163-205)	0.24
- Median GA (in weeks) (range)	27 (23 + 6 - 29 + 5)	27 (23 + 2 - 29 + 2)	
- Median birth weight (in g) (IQR 25-75%)	940 (460-1256)	870 (367-1185)	0.16
- Male (%)	181 (60.9)	171 (60.4)	0.90
- Outborn (%)	34 (11.4)	23 (8.1)	0.18
- APGAR score at 1 min (IQR 25-75%)	6 (4-8)	6 (4-8)	0.64
- APGAR score at 5 min (IQR 25-75%)	8 (7-9)	8 (7-9)	0.75
Maternal characteristics/delivery			
- Antenatal steroids			
- Complete course (%)	159 (53.5)	174 (61.5)	0.12
- Incomplete course (%)	56 (18.9)	65 (23)	
- Unknown/none (%)	11/71 (27.6)	6/38 (15.5)	
- ROM‡ > 18 hours prior birth (%)	81 (27.3)	86 (30.4)	0.41
- Clinical chorioamnionitis (%)	27 (9.1)	27 (9.5)	0.85
- Histopathological chorioamnionitis (%)	104 (35.0)	109 (38.5)	0.38
- Antepartum haemorrhage (%)	62 (20.9)	69 (24.4)	0.15
- Pre-eclampsictoxaemia (%)	58 (19.5)	55 (19.4)	0.15
- Spontaneous preterm labour (%)	190 (64.0)	169 (59.7)	0.20
- Caesarean section (%)	211 (71.0)	185 (65.4)	0.14
- Abnormal dopplers/fetal distress/non-reassuring CTG (%)	14 (4.7)	16 (5.7)	0.61
Feeding			

- Age at introduction of minimal enteral feeds (days)			
(median, IQR 25-75%)	2 (1-2)	2 (1-2)	0.27
- Type of feeding at starting first minimal enteral feeds			
- Expressed breast milk (%)	238 (80.1)	236 (83.4)	0.59
- Formula or mixed (%)	52 (17.5)	41 (14.5)	
- Unknown/died	2/5 (2.4)	1/5 (2.1)	
Persistent ductus arteriosus requiring treatment with Ibuprofen			
- Persistent ductus arteriosus (%)	60 (20.2)	58 (20.5)	0.93

†GA = Gestational Age; ‡ROM = Rupture of Membranes.

Table 2: Primary outcomes.

	Period 1	Period 2	P-value	Odds ratio (confidence interval)
	Control group	Treatment group		
	No probiotics	Infloran		
	(N = 297)	(N = 283)		
Incidence of NEC[†] (%)				
- All cases	21 (7.1)	10 (3.5)	0.07	0.48 (0.20-1.09)
- Suspected NEC	8 (2.7)	7 (2.5)	1.00	0.92 (0.28-2.94)
- Confirmed NEC ≥ stage II	13 (4.4)	3 (1.1)	0.02	0.23 (0.04-0.87)
Incidence of death (any cause) (%)				
- Incidence of death (secondary to NEC)	5 (1.7)	2 (0.7)	0.45	0.42 (0.04-2.57)

†NEC = Necrotising Enterocolitis.

weight, gender, percentage of out born babies, Apgar scores, type of feeding at introduction of feeds, age at starting feeds or incidence of PDA requiring treatment with Ibuprofen.

Maternal characteristics were also similar in both groups (Table 1). There were no significant differences in the incidences of prolonged rupture of membranes, clinical or histopathological chorioamnionitis, antepartum haemorrhage, pre-eclamptic toxemia, spontaneous onset of preterm labour and caesarean section. While administration of antenatal steroids was similar in both groups of infants < 32 weeks of gestation, there was a significant difference in the subgroup analysis of ELBW infants (48.3% in the control group versus 69.4% in the treatment group, p-value 0.01).

The rate of confirmed NEC was significantly lower in the treatment group compared with the control group (1.1% versus 4.4%, p-value 0.02, odds ratio 0.23, confidence interval 0.04-0.87) (Table 2). This was also the case in the subgroup of ELBW infants (12.4% versus 2%, p-value 0.008, odds ratio 0.15, confidence interval 0.02-0.71). This result remained significant after performing a logistic regression to adjust for the difference in antenatal steroid administration (p-value 0.03, odds ratio 0.18, confidence interval 0.03-0.73). According to our data, the number needed to treat to prevent one case of NEC was 30 patients. In the subgroup of ELBW infants the number needed to treat was 10.

The incidence of death was similar in both groups (6.7% in the control group versus 8.1% in the treatment group, p-value 0.53) (Table 2).

There were no statistically significant differences between the groups in time to reach full feeds, requirement and duration of parenteral nutrition, requirement and duration of central lines (umbilical venous catheter and PICC lines) or duration of hospital stay. Infants in the treatment group regained their birth weight slightly sooner than infants in the control group (median day 11 versus day 12, p 0.03) (Table 3). This was also true for ELBW infants (median day 10.4 versus day 12, p 0.04).

Discussion

This study found that routine administration of probiotics reduces the incidence of NEC in preterm infants born at < 32 weeks' gestation. Our baseline rate of 4.4% NEC cases in the control group was comparable to the rates described in recent randomised controlled trials (RCTs) worldwide which ranged from 2.8 to 6.5% [59-65]. Our rate was decreased to 1.1%. The reduced NEC rates in the probiotic group in the majority of these RCTs ranged from 1.1 to 4.4% [60-65]. One randomised controlled trial found no cases of NEC in the probiotic group, however this could be due to relatively small sample size [59]. Our reduction in the rate of NEC from 4.4% to 1.1% is similar to a recent multicentre randomised controlled trial in Australia and New Zealand that described a decrease from 4.4% to 2% [58]. These results suggest that the reduction in the rate of NEC following administration of probiotics found in several international studies was applicable to our units' population.

A recent multicentre, randomised controlled

Table 3: Secondary outcomes.

	Period 1	Period 2	P-value	95% confidence interval
	Control group	Treatment group		
	No probiotics	Infloran		
	(N = 297)	(N = 283)		
Time to establish feeds (days)				
- 50 mls/kg/d (median, IQR 25-75%)	5 (4-7)	5 (4-8)	0.31	-
- 100 mls/kg/d (median, IQR 25-75%)	7 (5-10)	7 (5-10)	0.15	-
- 150 mls/kg/d (median, IQR 25-75%)	8 (7-11.75)	9 (7-12)	0.32	-
Time to regain birth weight (days)				
- (median, IQR 25-75%)	12 (9-16)	11 (8-14)	0.03	0.08-1.69
Parenteral nutrition				
- Infants requiring parenteral nutrition (%)	193 (65.0)	191 (67.5)	0.52	-
- Duration of parenteral nutrition (days)	9 (7-13)	9 (7-12)	0.48	-
Central lines				
- UVC † (%)	125 (42.1)	132 (46.6)	0.27	-
- Duration UVC (days) (median, IQR 25-75%)	6 (4-8)	6 (4-8)	0.84	-
- PICC ‡ line (%)	146 (49.2)	149 (52.7)	0.40	-
- Duration PICC lines (days) (median, IQR 25-75%)	8 (7-13)	8 (6-13)	0.58	-
Duration of hospitalization				
- (median, IQR 25-75%)	58 (40.25-80.75)	57 (41-78)	0.89	-

†UVC = Umbilical Venous Catheter; ‡PICC line = Peripherally Inserted Central Catheter.

Table 4: Confirmed NEC § cases in both groups.

	GA † at birth	Birth weight (gram)	NEC stage	CGA ‡ at diagnosis	Actual age at diagnosis (days)	Death secondary to NEC§	Need for surgery	
Control group	1	30 + 0	1370	II B	33 + 4	25		No
	2	26 + 2	946	III A	28 + 5	17	Yes	No
	3	25 + 0	570	III A	28 + 4	25	Yes	Yes
	4	28 + 1	520	III B	29 + 0	6		Yes
	5	26 + 5	960	III A	28 + 5	14	Yes	No
	6	29 + 5	960	III B	35 + 0	37	Yes	No
	7	29 + 2	1310	II B	34 + 1	34		No
	8	24 + 5	710	III B	26 + 0	9	Yes	No
	9	27 + 5	880	III A	28 + 5	7		No
	10	25 + 6	824	II A	31 + 6	42		No
	11	24 + 5	840	II A	30 + 4	41		No
	12	24 + 5	734	II B	31 + 4	48		No
	13	28 + 2	640	II B	30 + 4	16		No
Treatment group	1	24 + 0	630	II B	29 + 0	35	Yes	Yes
	2	27 + 5	940	III B	30 + 4	20		Yes
	3	30 + 3	1120	III A	37 + 1	47	Yes	No

†GA = Gestational Age; ‡CGA = Corrected Gestational Age; §NEC = Necrotising Enterocolitis; ¶IUGR = Intrauterine Growth Retardation.

phase 3 study testing the effectiveness of the probiotic *Bifidobacterium breve* to reduce NEC, late-onset sepsis, and death was negative for all clinical outcomes [66]. This might be due to the choice and dosing of probiotic strain [56]. Interestingly, there was also a high colonisation rate of the placebo group which might have masked any benefit of the probiotic intervention [66].

In our study the majority of NEC cases occurred in ELBW infants (Table 4). This is consistent with ANZNN data that reported NEC rates of 0.8-1.2% in infants born after 28 weeks' gestation but up to 10.4% in infants born prior 28 weeks' gestation [6]. There is insufficient data with regard to the benefits of probiotic supplementation in the most at risk infants weighing less than 1000 grams at birth. To our knowledge there are only two studies that compared NEC rates in ELBW infants and neither of them could show a significant reduction [57,58]. This might be due to small sample size in one of the studies [57], but also due to relatively low baseline rates of NEC in the control groups of both studies [57,58]. Our study indicates that probiotics were effective in decreasing the rate of NEC in this susceptible patient group.

It is known that treatment with antenatal corticosteroids is associated with a reduction in NEC [29,30]. There were a higher percentage of women who received a complete course of antenatal steroids in the treatment group which could have contributed to the lower incidence of NEC. We addressed this by performing a logistic regression analysis. The incidence of NEC remained significantly lower in the treatment group after adjusting for antenatal steroid administration.

A limitation of the study is that we do not know how many babies in the cohort may have received donor breast milk. While there is strong evidence that both mothers' own milk and donor breast milk reduce the incidence of NEC compared to formula feeding, there are no trials comparing mothers' own milk and donor breast milk [23-25]. We compared the percentage of infants that received human milk only at introduction of feeds (including mothers' own milk as well as donor milk) and found no significant differences between the groups.

When probiotics were first introduced in our unit, all infants already admitted to the unit were assessed whether they met the criteria for probiotic treatment. Those who were born < 32 weeks and had a corrected age of < 36 weeks were commenced on probiotics as soon as parental consent had been obtained. There was one infant allocated to the treatment group who was 46 days old when probiotics were commenced but had already been diagnosed with NEC on day 17 of life. We excluded this infant from the study. Including this infant into the treatment group on an intention to treat basis still showed a significant reduction in the incidence of NEC (1.4% versus 4.4%, p-value 0.047, odds ratio 0.31, confidence interval 0.07-1.03).

Debate still remains about the safety of probiotics [54,56]. While several meta-analyses didn't reveal any significant side effects [45,46,48-50], there are case reports of *Bifidobacterium* bacteraemia in preterm infants on probiotic therapy [52,53]. In our study, reassuringly there were no confirmed episodes of sepsis with the administered probiotic species.

There is ongoing controversy about the most effective preparations of probiotics, as well as timing and length of therapy [55]. The available studies do not focus on one specific product or dosing regimen, however both the administration of *Lactobacillus* species and a mixture of probiotics significantly reduced the incidence of severe stage II to III NEC in several trials [45]. Infloran has previously been used in randomised controlled trials with good effect [62,63]. According to our data, the number needed to treat to prevent one case of NEC was 30 patients. In the subgroup of ELBW infants the number needed to treat was 10. In conclusion, routine administration of probiotics was effective in decreasing the incidence of NEC in very low and extremely low birth weight infants in our population. Other Australian units should also consider its use for the prevention of NEC.

References

1. Kafetzis DA, Skevaki C, Costalos C (2003) Neonatal necrotizing enterocolitis: An overview. *Current Opinion in Infectious Diseases* 16: 349-355.
2. Maheshwari A, Carlo WA (2015) Digestive system disorders. In: Kliegman R, Stanton B, St Geme J, Schor N. *Nelson Textbook of Pediatrics Expert Consult*. (20th edn), Elsevier Health Sciences, London.
3. Horbar JD, Badger GJ, Carpenter JH, et al. (2002) Trends in mortality and morbidity for very low birth weight infants, 1991-1999. *Pediatrics* 110: 143-151.
4. Lee SK, McMillan DD, Ohlsson A, et al. (2000) Variations in practice and outcomes in the Canadian NICU network: 1996-1997. *Pediatrics* 106: 1070-1079.
5. Sankaran K, Puckett B, Lee DS, et al. (2004) Variations in incidence of necrotizing enterocolitis in Canadian neonatal intensive care units. *J Pediatr Gastroenterol Nutr* 39: 366-372.
6. Chow S, Marsney R, Hossain S, et al. (2013) Report of the Australian and New Zealand neonatal network 2010, ANZNN, Sydney, Australia.
7. Ballance WA, Dahms BB, Shenker N, et al. (1990) Pathology of neonatal necrotizing enterocolitis: A ten-year experience. *J Pediatr* 117: S6-S13.
8. Huda S, Chaudhery S, Ibrahim H, et al. (2014) Neonatal necrotizing enterocolitis: Clinical challenges, pathophysiology and management. *Pathophysiology* 21: 3-12.
9. Kliegman RM, Walker WA, Yolken RH (1993) Necrotizing enterocolitis: Research agenda for a disease of unknown etiology and pathogenesis. *Pediatric research* 34: 701-708.
10. Neu J (1996) Necrotizing enterocolitis: The search for a unifying pathogenic theory leading to prevention. *Pediatr Clin North Am* 43: 409-432.
11. Cotten CM, Taylor S, Stoll B, et al. (2009) Prolonged duration of initial empirical antibiotic treatment is associated with increased rates of necrotizing enterocolitis and death for extremely low birth weight infants. *Pediatrics* 123: 58-66.
12. Guillet R, Stoll BJ, Cotten CM, et al. (2006) Association of H2-blocker therapy and higher incidence of necrotizing enterocolitis in very low birth weight infants. *Pediatrics* 117: e137-e142.
13. Berseth CL (2005) Feeding strategies and necrotizing enterocolitis. *Curr Opin Pediatr* 17: 170-173.

14. Clark DA, Miller MJ (1990) Intraluminal pathogenesis of necrotizing enterocolitis. *J Pediatr* 117: S64-S67.
15. De Plaen IG (2013) Inflammatory signaling in necrotizing enterocolitis. *Clin Perinatol* 40: 109-124.
16. Hunter CJ, Upperman JS, Ford HR, et al. (2008) Understanding the susceptibility of the premature infant to necrotizing enterocolitis (NEC). *Pediatr Res* 63: 117-123.
17. Kandasamy J, Huda S, Ambalavanan N, et al. (2014) Inflammatory signals that regulate intestinal epithelial renewal, differentiation, migration and cell death: Implications for necrotizing enterocolitis. *Pathophysiology* 21: 67-80.
18. Morowitz MJ, Poroyko V, Caplan M, et al. (2010) Redefining the role of intestinal microbes in the pathogenesis of necrotizing enterocolitis. *Pediatrics* 125: 777-785.
19. Nowicki P (1990) Intestinal ischemia and necrotizing enterocolitis. *J Pediatr* 117: S14-S19.
20. Ramani M, Ambalavanan N (2013) Feeding practices and necrotizing enterocolitis. *Clin Perinatol* 40: 1-10.
21. Schanler RJ, Shulman RJ, Lau C (1999) Feeding strategies for premature infants: Beneficial outcomes of feeding fortified human milk versus preterm formula. *Pediatrics* 103: 1150-1157.
22. Stewart CJ, Marrs ECL, Magorrian S, et al. (2012) The preterm gut microbiota: Changes associated with necrotizing enterocolitis and infection. *Acta Paediatr* 101: 1121-1127.
23. Lucas A, Cole TJ (1990) Breast milk and neonatal necrotising enterocolitis. *Lancet* 336: 1519-1523.
24. Meinzen-Derr J, Poindexter B, Wrage L, et al. (2009) Role of human milk in extremely low birth weight infants' risk of necrotizing enterocolitis or death. *J Perinatol* 29: 57-62.
25. Quigley M, McGuire W (2014) Formula versus donor breast milk for feeding preterm or low birth weight infants. *Cochrane Database Syst Rev*.
26. Dollberg S, Lusky A, Reichman B (2005) Patent ductus arteriosus, indomethacin and necrotizing enterocolitis in very low birth weight infants: A population-based study. *J Pediatr Gastroenterol Nutr* 40: 184-188.
27. Dorling J, Kempley S, Leaf A (2005) Feeding growth restricted preterm infants with abnormal antenatal doppler results. *Arch Dis Child Fetal Neonatal Ed* 90: 359-363.
28. Singh R, Shah BL, Frantz ID 3rd (2012) Necrotizing enterocolitis and the role of anemia of prematurity. *Semin Perinatol* 36: 277-282.
29. Roberts D, Dalziel S (2006) Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. *Cochrane Database Syst Rev*.
30. Wong D, Abdel-Latif M, Kent A (2014) Antenatal steroid exposure and outcomes of very premature infants: A regional cohort study. *Arch Dis Child Fetal Neonatal Ed* 99: 12-20.
31. Hällström M, Koivisto AM, Janas M, et al. (2006) Laboratory parameters predictive of developing necrotizing enterocolitis in infants born before 33 weeks of gestation. *J Pediatr Surg* 41: 792-798.
32. Kenton AB, O'Donovan D, Cass DL, et al. (2005) Severe thrombocytopenia predicts outcome in neonates with necrotizing enterocolitis. *J Perinatol* 25: 14-20.
33. Bell MJ, Ternberg JL, Feigin RD, et al. (1978) Neonatal necrotizing enterocolitis. Therapeutic decisions based upon clinical staging. *Ann Surg* 187: 1-7.
34. Kliegman RM, Walsh MC (1987) Neonatal necrotizing enterocolitis: Pathogenesis, classification, and spectrum of illness. *Curr Probl Pediatr* 17: 213-288.
35. Fitzgibbons SC, Jaksic T, Ching Y, et al. (2009) Mortality of necrotizing enterocolitis expressed by birth weight categories. *J Pediatr Surg* 44: 1072-1076.
36. Sinha S, Miall L, Jardine L (2016) *Essential neonatal medicine*. John Wiley & Sons. (6th edn), Chichester, West Sussex, England.
37. Kastenberg ZJ, Sylvester KG (2013) The surgical management of necrotizing enterocolitis. *Clin Perinatol* 40: 135-148.
38. Gutierrez IM, Kang KH, Jaksic T (2011) Neonatal short bowel syndrome. *Seminars in Fetal and Neonatal Medicine* 16: 157-163.
39. Fuller R (1989) Probiotics in man and animals. *J Appl Bacteriol* 66: 365-378.
40. Link-Amster H, Rochat F, Saudan KY, et al. (1994) Modulation of a specific humoral immune response and changes in intestinal flora mediated through fermented milk intake. *FEMS Immunol Med Microbiol* 10: 55-63.
41. Martin CR, Walker WA (2008) Probiotics: Role in pathophysiology and prevention in necrotizing enterocolitis. *Semin Perinatol* 32: 127-137.
42. Millar M, Wilks M, Costeloe K (2003) Probiotics for preterm infants? *Arch Dis Child Fetal Neonatal Ed* 88: 354-358.
43. Mattar AF, Drongowski RA, Coran AG, et al. (2001) Effect of probiotics on enterocyte bacterial translocation in vitro. *Pediatr Surg Int* 17: 265-268.
44. Reid G, Howard J, Gan BS (2001) Can bacterial interference prevent infection? *Trends Microbiol* 9: 424-428.
45. AlFaleh K, Anabrees J (2014) Probiotics for prevention of necrotizing enterocolitis in preterm infants. *Cochrane Database Syst Rev*.
46. Deshpande G, Rao S, Patole S, et al. (2010) Updated meta-analysis of probiotics for preventing necrotizing enterocolitis in preterm neonates. *Pediatrics* 125: 921-930.
47. Bernardo WM, Aires FT, Carneiro RM, et al. (2013) Effectiveness of probiotics in the prophylaxis of necrotizing enterocolitis in preterm neonates: A systematic review and meta-analysis. *J Pediatr (Rio J)* 89: 18-24.
48. Guthmann F, Kluthe C, Buhner C (2010) Probiotics for prevention of necrotising enterocolitis: An updated meta-analysis. *Klin Padiatr* 222: 284-290.
49. Wang Q, Dong J, Zhu Y (2012) Probiotic supplement reduces risk of necrotizing enterocolitis and mortality in preterm very low-birth-weight infants: An updated meta-analysis of 20 randomized, controlled trials. *J Pediatr Surg* 47: 241-248.
50. Yang Y, Guo Y, Kan Q, et al. (2014) A meta-analysis of probiotics for preventing necrotizing enterocolitis in preterm neonates. *Braz J Med Biol Res* 47: 804-810.
51. Mihatsch WA, Braegger CP, Decsi T, et al. (2012) Critical systematic review of the level of evidence for routine use of probiotics for reduction of mortality and prevention of necrotizing enterocolitis and sepsis in preterm infants. *Clin Nutr* 31: 6-15.

52. Bertelli C, Pillonel T, Torregrossa A, et al. (2015) Bifidobacterium longum bacteremia in preterm infants receiving probiotics. Clin Infect Dis 60: 924-927.
53. Zbinden A, Zbinden R, Berger C, et al. (2015) Case series of bifidobacterium longum bacteremia in three preterm infants on probiotic therapy. Neonatology 107: 56-59.
54. Ofek Shlomai N, Deshpande G, Rao S, et al. (2014) Probiotics for preterm neonates: What will it take to change clinical practice? Neonatology 105: 64-70.
55. Deshpande GC, Rao SC, Keil AD, et al. (2011) Evidence-based guidelines for use of probiotics in preterm neonates. BMC Med 9: 92.
56. Abrahamsson TR (2016) Not all probiotic strains prevent necrotizing enterocolitis in premature infants. Lancet 387: 624-625.
57. Al-Hosni M, Duenas M, Hawk M, et al. (2012) Probiotics-supplemented feeding in extremely low-birth-weight infants. J Perinatol 32: 253-259.
58. Jacobs SE, Tobin JM, Opie GF, et al. (2013) Probiotic effects on late-onset sepsis in very preterm infants: A randomized controlled trial. Pediatrics 132: 1055-1062.
59. Braga TD, da Silva GA, de Lira PI, et al. (2011) Efficacy of bifidobacterium breve and lactobacillus casei oral supplementation on necrotizing enterocolitis in very-low-birth-weight preterm infants: A double-blind, randomized, controlled trial. Am J Clin Nutr 93: 81-86.
60. Dani C, Biadaioli R, Bertini G, et al. (2002) Probiotics feeding in prevention of urinary tract infection, bacterial sepsis and necrotizing enterocolitis in preterm infants. A prospective double-blind study. Biol Neonate 82: 103-108.
61. Demirel G, Erdeve O, Celik IH, et al. (2013) Saccharomyces boulardii for prevention of necrotizing enterocolitis in preterm infants: A randomized, controlled study. Acta Paediatr 102: e560-e565.
62. Lin HC, Hsu CH, Chen HL, et al. (2008) Oral probiotics prevent necrotizing enterocolitis in very low birth weight preterm infants: A multicenter, randomized, controlled trial. Pediatrics 122: 693-700.
63. Lin HC, Su BH, Chen AC, et al. (2005) Oral probiotics reduce the incidence and severity of necrotizing enterocolitis in very low birth weight infants. Pediatrics 115: 1-4.
64. Manzoni P, Rinaldi M, Cattani S, et al. (2009) Bovine lactoferrin supplementation for prevention of late-onset sepsis in very low-birth-weight neonates: A randomized trial. JAMA 302: 1421-1428.
65. Rojas MA, Lozano JM, Rojas MX, et al. (2012) Prophylactic probiotics to prevent death and nosocomial infection in preterm infants. Pediatrics 130: e1113-e1120.
66. Costeloe K, Hardy P, Juszczak E, et al. (2016) Bifidobacterium breve BBG-001 in very preterm infants: A randomised controlled phase 3 trial. Lancet 387: 649-660.

